Intensive Induction for Newly Diagnosed Acute Myelogenous Leukemia
- Determine the complete remission rate in patients with acute myelogenous leukemia
treated with induction chemotherapy comprising mitoxantrone hydrochloride, cytarabine,
- Determine the feasibility and toxicity of this regimen when given to patients with
newly diagnosed acute myelogenous leukemia.
OUTLINE: Patients receive induction chemotherapy comprising mitoxantrone hydrochloride IV on
days 1-3, cytarabine IV continuously over 72 hours on days 1-3 and 8-10, and etoposide IV
continuously over 72 hours on days 8-10. Patients also receive filgrastim (G-CSF)
subcutaneously once daily beginning on day 4 and continuing until blood counts recover.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Matt E. Kalaycio, MD
The Cleveland Clinic
United States: Federal Government